Search

Your search keyword '"Kloecker, David E"' showing total 22 results
Start Over Author "Kloecker, David E"
22 results on '"Kloecker, David E"'

2. Translating trial results into interpretable risk estimates: Systematic analysis of cardiorenal outcome trials of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors.

Author

Rizzi, Alessandro, Kloecker, David E., Pitocco, Dario, Khunti, Kamlesh, Davies, Melanie J., and Zaccardi, Francesco

Abstract

In a randomised controlled trial (RCT), the between-arm difference in the average probability of an event per unit of time (i.e., yearly incidence risk difference, YIRD) is an easy-to-interpret treatment effect metric. We aimed to quantify the YIRD in cardiorenal RCTs of GLP-1RAs or SGLT-2is. We digitally searched for RCTs published up to March 1st, 2023, including subjects with type 2 diabetes randomised to GLP-1RAs or SGLT-2is and investigating cardiorenal outcomes or death. We extracted information from Kaplan-Meier (KM) plots to obtain time-to-event individual data and estimate within-arm yearly incidence risk and YIRD. Data from 19 RCTs (28 kM plots) were analysed: comparing treatment to placebo, in GLP-1RA RCTs the YIRD ranged from 0.2 % (95 % CI: −0.7 %, 1.1 %) to −1.9 % (−3.1, −0.7), for primary outcome; and from −0.2 % (−0.5, 0.2) to −0.4 % (−0.7 %, −0.0 %), for mortality. With the exception of SOLOIST-WHF (YIRD 11.9 % for primary outcome), corresponding estimates in SGLT-2is RCTs were: from −0.1 % (−0.4, 0.1) to −5.0 % (−7.7, −2.6), for primary outcome; and from −0.1 % (−0.2, 0.1) to −1.9 % (−4.4 %, 0.6 %), for mortality. The YIRD metric complements other relative treatment effect estimates and helps quantify the absolute benefit of GLP-1RAs and SGLT-2is. • Yearly incidence risk difference (YIRD) can help interpreting treatment effect. • Using reconstructed time-to-event data, we estimated YIRD in cardiorenal trials. • YIRDs was estimated for primary outcomes and death in GLP1-RAs and SGLT2-is trials. • YIRD is easy-to-interpret and could add insights in clinical decision-making. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Additional file 1 of Patterns of multimorbidity and risk of severe SARS-CoV-2 infection: an observational study in the U.K

Author

Chudasama, Yogini V., Zaccardi, Francesco, Gillies, Clare L., Razieh, Cameron, Yates, Thomas, Kloecker, David E., Rowlands, Alex V., Davies, Melanie J., Islam, Nazrul, Seidu, Samuel, Forouhi, Nita G., and Khunti, Kamlesh

Abstract

Additional file 1: Figure S1. Flow chart of participants included in the UK Biobank Study. Table S1. Literature search on the most common pre-existing comorbidities in patients with severe SARS-CoV-2 infection. Table S2. Association between multimorbidity index using 3 or more conditions and risk of severe SARS-CoV-2 infection. Table S3. Sensitivity analyses using vitamin D levels at follow-up and last recorded air pollution levels. Table S4. Sensitivity analyses considering time in the study and removing cardiorespiratory fitness and C-reactive protein from the model. Checklist S1. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE).

Published
2021
Full Text
View/download PDF

14. Association of Timing and Balance of Physical Activity and Rest/Sleep With Risk of COVID-19: A UK Biobank Study

Author

Rowlands, Alex V., primary, Kloecker, David E., additional, Chudasama, Yogini, additional, Davies, Melanie J., additional, Dawkins, Nathan P., additional, Edwardson, Charlotte L., additional, Gillies, Clare, additional, Khunti, Kamlesh, additional, Razieh, Cameron, additional, Islam, Nazrul, additional, Zaccardi, Francesco, additional, and Yates, Tom, additional

Published
2021
Full Text
View/download PDF

16. Patterns of Multimorbidity and Risk of Severe SARS-CoV-2 Infection: an observational study in the U.K

Author

Chudasama, Yogini V, primary, Zaccardi, Francesco, additional, Gillies, Clare L, additional, Razieh, Cameron, additional, Yates, Thomas, additional, Kloecker, David E, additional, Rowlands, Alex V, additional, Davies, Melanie J, additional, Islam, Nazrul, additional, Seidu, Samuel, additional, Forouhi, Nita G, additional, and Khunti, Kamlesh, additional

Published
2020
Full Text
View/download PDF

20. Efficacy and tolerability of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A systematic review and network meta‐analysis

Author

Hussein, Humaira, primary, Zaccardi, Francesco, additional, Khunti, Kamlesh, additional, Davies, Melanie J., additional, Patsko, Emily, additional, Dhalwani, Nafeesa N., additional, Kloecker, David E., additional, Ioannidou, Ekaterini, additional, and Gray, Laura J., additional

Published
2020
Full Text
View/download PDF

22. Use of Metformin and Cardiovascular Effects of New Classes of Glucose-Lowering Agents: A Meta-analysis of Cardiovascular Outcome Trials in Type 2 Diabetes.

Author

Zaccardi, Francesco, Kloecker, David E., Buse, John B., Mathieu, Chantal, Khunti, Kamlesh, and Davies, Melanie J.

Subjects
*TYPE 2 diabetes, *CARDIOVASCULAR agents, *METFORMIN
Abstract

The article discusses a study that examined the differences in the treatment effect of incretins and sodium-glucose cotransporter 2 inhibitors on cardiovascular outcomes according to metformin use. Highlights include cardiovascular treatment effect in participants with metformin at baseline, characteristics that may differ between patients with and without metformin, and the absolute treatment effect in relation to medication costs and multiple patient characteristics.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results